Returning from ASCO 2024, Avan J. Armaghani, MD, highlights two significant studies regarding adjuvant endocrine therapy in ER-low populations and the NATALEE study for patients with node-negative breast cancer. The studies underscore the challenge in managing patients with tumors with ER 1%-10% positivity, revealing high omission rates of adjuvant endocrine therapy and associated increased risk for death.
Dr Armaghani emphasizes the need for further research to identify which patients benefit most from such therapies. Additionally, Dr Armaghani discusses the expanded use of adjuvant ribociclib for patients with node-negative breast cancer, stressing the importance of weighing risks and benefits.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASCO 2024: Navigating New Data in Early Breast Cancer - Medscape - Jun 25, 2024.
Comments